All In the pipeline articles – Page 6
-
OpinionIgnorance is no defence
In a chemistry lab, what you don’t know really can hurt you, says Derek Lowe
-
OpinionProgress at the pace of the slowest
Chemistry is rarely the rate-limiting process in getting a drug to market, says Derek Lowe
-
OpinionChemical space is big. Really big
You think it’s a long way to the back of your screening libraries? That’s peanuts to chemical space, says Derek Lowe
-
OpinionGarbage in, garbage out
The rise of low-quality and predatory open access journals and conferences worries Derek Lowe
-
OpinionDeath of a reagent
Fashion and progress combine to mean some reactions and reagents persist, while others fall by the wayside, says Derek Lowe
-
OpinionThe crystal ball that can tell lies
X-ray structures are not necessarily definitive, says Derek Lowe, especially when it comes to biomolecules
-
OpinionToo big to innovate?
How strong is the correlation between company size and research productivity, asks Derek Lowe
-
OpinionMessy megamergers
Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe
-
OpinionEngineering serendipity
It takes more than random stumbling to find new reactions, says Derek Lowe
-
OpinionKnown unknowns
New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe
-
OpinionTools of the trade
Derek Lowe wonders what the most life-changing instrument for organic chemists is, and what might be missing from the toolbox
-
OpinionBeelzebub Pharma Ltd
Derek Lowe thinks the Devil’s R&D management schemes might be scarily familiar
-
OpinionIs there a drug for that?
Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places
-
OpinionRolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
-
OpinionNatural born chemists
Redesigning nature’s catalysts is tantalising but tricky, says Derek Lowe
-
OpinionWhat's the use?
Not every reaction can be run in a bucket, says Derek Lowe, but there are limits to what should be classed as ‘useful’
-
-
OpinionKnowledge lost or time gained?
Derek Lowe wonders whether we should mourn the decline of classic analytical techniques or embrace technological advances
-
OpinionLab’s labourers lost?
How long should scientists stay at the bench, asks Derek Lowe. How long is a piece of string?
-
OpinionTarget acquired
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be